Real-world analysis of brain atrophy in multiple sclerosis patients with an artificial intelligence based software tool
-
Published:2024-08-08
Issue:1
Volume:6
Page:
-
ISSN:2524-3489
-
Container-title:Neurological Research and Practice
-
language:en
-
Short-container-title:Neurol. Res. Pract.
Author:
Reinhardt CarolineORCID, Angstwurm Klemens, Freudenstein David, Lee De-Hyung, Wendl Christina, Linker Ralf A.
Abstract
Abstract
Background
Atrophy of white and grey matter volumes occurs early in the brains of people with multiple sclerosis (pwMS) and has great clinical relevance. In clinical trials, brain atrophy can be quantified by magnetic resonance imaging (MRI) with automated software tools.
Methods
In this study, we analyze volumes of various brain regions with the software “md brain” based on routine MRI scans of 53 pwMS in a real-world setting. We compare brain volumes of pwMS with an EDSS ≥ 3.5 and a disease duration ≥ 10 years to the brain volumes of pwMS with an EDSS < 3.5 and a disease duration < 10 years as well as with or without immunotherapy.
Results
pwMS with an EDSS ≥ 3.5 and a disease duration ≥ 10 years had significantly lower volumes of the total brain, the grey matter and of the frontal, temporal, parietal and occipital lobe regions as compared to pwMS with an EDSS < 3.5 and a disease duration < 10 years. Regional brain volumes were significantly lower in pwMS without immunotherapy.
Conclusions
The study showed that higher EDSS, longer disease duration and absence of immunotherapy was associated with lower volumes in a number of brain regions. Further real-world studies may include larger patient cohorts in longitudinal analyses.
Funder
Universität Regensburg
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis—A review. European Journal of Neurology, 26(1), 27–40. https://doi.org/10.1111/ene.13819 2. Rocca, M. A., Battaglini, M., Benedict, R. H., De Stefano, N., Geurts, J. J., Henry, R. G., Horsfield, M. A., Jenkinson, M., Pagani, E., & Filippi, M. (2017). Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology, 88(4), 403–413. https://doi.org/10.1212/WNL.0000000000003542 3. Chard, D. T., Griffin, C. M., Parker, G. J., Kapoor, R., Thompson, A. J., & Miller, D. H. (2002). Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain, 125(Pt 2), 327–337. https://doi.org/10.1093/brain/awf025 4. Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E. W., Sprenger, T., Sormani, M. P., Smith, T., Haring, D. A., Piani Meier, D., & Tomic, D. (2016). Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Multiple Sclerosis, 22(10), 1297–1305. https://doi.org/10.1177/1352458515616701 5. De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., & Kieseier, B. C. (2014). Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs, 28(2), 147–156. https://doi.org/10.1007/s40263-014-0140-z
|
|